Non-adherence to Aspirin or Oral Anticoagulants in Secondary Prevention After Ischaemic Stroke

Overview

Journal J Neurol

Specialty Neurology

Date 2005 May 4

PMID 15868068

Citations 26

Authors

E L L M de Schryver

J van Gijn

L J Kappelle

P J Koudstaal

A Algra

Affiliations

Soon will be listed here.

Abstract

Background: The effectiveness of medication is influenced by treatment adherence. After TIA or minor disabling stroke patients usually are advised to take antithrombotic medication. Stroke patients are an interesting group of patients with respect to adherence, since cardiovascular risk factors and stroke may (indirectly) negatively influence brain function, which can affect adherence. We investigated determinants of non-adherence in patients who used aspirin or oral anticoagulation after cerebral ischaemia of arterial origin.

Methods: Data of patients prospectively followed in two clinical trials (the Dutch TIA Trial and the Stroke Prevention In Reversible Ischaemia Trial) were analysed with Cox proportional hazards modelling.

Results: In the two trials 3796 patients were treated with aspirin. During a mean follow-up of 2.1 years, 689 patients (18%) prematurely stopped treatment, 305 (8 %) did so without a clear medical reason (non-adherence). Age >or= 65 years and the use of 300 instead of 30 mg of aspirin were independently associated with non-adherence. Diastolic blood pressure of >or= 90 mmHg and dizziness were associated with better adherence. Of 651 patients on oral anticoagulation, 143 patients (22 %) stopped after a mean follow-up of 1.0 year, 66 (10 %) did so because of nonadherence. No statistically significant determinants for non-adherence were identified.

Conclusion: As found in the literature on nonadherence in general, age of >or= 65 years and a higher dose of aspirin (300 mg versus 30 mg) were independently associated with non-adherence with aspirin treatment that was prescribed for secondary prevention after cerebral ischaemia of arterial origin. Older patients may require extra encouragement to continue antithrombotic treatment. Lower doses of aspirin may improve treatment adherence.

Citing Articles

Overcoming Low Adherence to Chronic Medications by Improving their Effectiveness using a Personalized Second-generation Digital System.

Bayatra A, Nasserat R, Ilan Y Curr Pharm Biotechnol. 2024; 25(16):2078-2088.

PMID: 38288794 DOI: 10.2174/0113892010269461240110060035.

Coping Strategies and Posttraumatic Growth Following Transient Ischemic Attack: A Qualitative Study.

Kindermann D, Grosse-Holz V, Andermann M, Ringleb P, Friederich H, Rizos T J Clin Med. 2023; 12(2).

PMID: 36675504 PMC: 9863589. DOI: 10.3390/jcm12020575.

Use of Complementary and Alternative Medicine and Adherence to Medication Therapy Among Stroke Patients: A Meta-analysis and Systematic Review.

Rajahthurai S, Farrukh M, Makmor-Bakry M, Tan H, Fatokun O, Mohd Saffian S Front Pharmacol. 2022; 13:870641.

PMID: 35721127 PMC: 9204087. DOI: 10.3389/fphar.2022.870641.

Prevalence and associated factors of premature discontinuation of antiplatelet therapy after ischemic stroke: a nationwide population-based study.

Kim S, Kwon O, Choi H, Lee E, Cho B, Yoon D BMC Neurol. 2021; 21(1):349.

PMID: 34507550 PMC: 8431917. DOI: 10.1186/s12883-021-02384-5.

The Needs and Barriers of Medication-Taking Self-Efficacy Among Poststroke Patients: Qualitative Study.

Appalasamy J, Subramanian P, Tan K, Seeta Ramaiah S, Joseph J, Chua S JMIR Nurs. 2021; 2(1):e14399.

PMID: 34345772 PMC: 8279437. DOI: 10.2196/14399.

References

Svensson S, Kjellgren K, Ahlner J, Saljo R . Reasons for adherence with antihypertensive medication. Int J Cardiol. 2000; 76(2-3):157-63. DOI: 10.1016/s0167-5273(00)00374-0. View

Gencheva E, Sloan M, Leurgans S, Raman R, Harris Y, Gorelick P . Attrition and non-compliance in secondary stroke prevention trials. Neuroepidemiology. 2004; 23(1-2):61-6. DOI: 10.1159/000073976. View

. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol. 1997; 42(6):857-65. DOI: 10.1002/ana.410420606. View

van Gijn J, Algra A, Kappelle J, Koudstaal P, van Latum A . A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991; 325(18):1261-6. DOI: 10.1056/NEJM199110313251801. View

Hamann G, Weimar C, Glahn J, Busse O, Diener H . Adherence to secondary stroke prevention strategies--results from the German Stroke Data Bank. Cerebrovasc Dis. 2003; 15(4):282-8. DOI: 10.1159/000069490. View

Mushlin A, Appel F . Diagnosing potential noncompliance. Physicians' ability in a behavioral dimension of medical care. Arch Intern Med. 1977; 137(3):318-321. DOI: 10.1001/archinte.137.3.318. View

Donovan J . Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care. 1995; 11(3):443-55. DOI: 10.1017/s0266462300008667. View

Schroeder K, Fahey T, Ebrahim S . How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004; 164(7):722-32. DOI: 10.1001/archinte.164.7.722. View

Kephart G, Sketris I, Kass K . Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey. Can J Cardiol. 1999; 15(3):291-6. View

10.

Smith N, Psaty B, Heckbert S, Tracy R, Cornell E . The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly. J Clin Epidemiol. 1999; 52(2):143-6. DOI: 10.1016/s0895-4356(98)00141-3. View

11.

Cleemput I, Kesteloot K . Economic implications of non-compliance in health care. Lancet. 2002; 359(9324):2129-30. DOI: 10.1016/S0140-6736(02)09114-6. View

12.

. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993; 342(8882):1255-62. View

13.

Hillen T, Dundas R, Lawrence E, Stewart J, Rudd A, Wolfe C . Antithrombotic and antihypertensive management 3 months after ischemic stroke : a prospective study in an inner city population. Stroke. 2000; 31(2):469-75. DOI: 10.1161/01.str.31.2.469. View

14.

Vermeire E, Hearnshaw H, Van Royen P, Denekens J . Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001; 26(5):331-42. DOI: 10.1046/j.1365-2710.2001.00363.x. View

15.

Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke H . Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke. 2001; 32(8):1884-9. DOI: 10.1161/01.str.32.8.1884. View